

# NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

## Request for Insured Coverage of Omalizumab for Chronic Idiopathic Urticaria

| PATIENT INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                    |                                      |                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------|----------------------|
| PATIENT SURNAME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | PATIENT GIVEN NAME | HEALTH CARD NUMBER                   | DATE OF BIRTH        |
| PATIENT ADDRESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |                                      |                      |
| INITIAL REQUEST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |                                      |                      |
| <b>Please advise how the patient meets the following criteria:</b><br><input type="checkbox"/> For the treatment of adults and adolescents (12 years of age or older) with moderate to severe chronic idiopathic urticaria (CIU)<br><input type="checkbox"/> Patient remains symptomatic (presence of hives and/or associated itching) despite optimum management with available oral therapies<br><input type="checkbox"/> Prescribed by a specialist (allergist, immunologist, dermatologist, etc.) or other authorized prescriber with knowledge of CIU treatment |                    |                                      |                      |
| <b>Baseline UAS7 Score:</b> _____ <b>Date:</b> _____                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                    |                                      |                      |
| Trialed Oral Therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Dose               | Duration                             | Outcome              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |                                      |                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |                                      |                      |
| RENEWAL REQUEST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |                                      |                      |
| <b>Continued coverage will be authorized if the patient has achieved:</b><br><input type="checkbox"/> Complete symptom control for less than 12 consecutive weeks; <b>OR</b><br><input type="checkbox"/> Partial response to treatment, defined as at least a $\geq 9.5$ point reduction in baseline urticaria activity score over 7 days (UAS7); <b>OR</b><br><input type="checkbox"/> Complete symptom control on omalizumab and tried stopping therapy but experienced symptom relapse of their urticaria while off treatment                                     |                    |                                      |                      |
| <b>Current UAS7 Score:</b> _____ <b>Date:</b> _____                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                    |                                      |                      |
| <b>Additional Comments (if applicable)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                    |                                      |                      |
| <b>PRESCRIBER NAME &amp; ADDRESS:</b><br><br><br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                    |                                      |                      |
| _____<br><b>LICENCE #</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                    | _____<br><b>PRESCRIBER SIGNATURE</b> | _____<br><b>DATE</b> |

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

**Please Return Form To:** Nova Scotia Pharmacare Programs  
P.O. Box 500, Halifax, NS B3J 2S1, Fax: (902) 496-4440